Skin cancer is the most often encountered malignant cancer which stands for about 1/3 of all medically confirmed cancers. Number of patients with diagnosed cancer of this type increases annually by 10 to 15%. Skin cancer belongs to the group of malicious in situ cancers, which hardly develops metastasis to other organs. Nevertheless considering the frequency of occurrence and localization, its importance should not be disregarded. The most often occurring skin cancer is basal cell carcinoma (BCC), which stands for about 65-75% of all skin cancers and about 25% of all diagnosed cases of cancer. Second most encountered skin cancer is squa-mous cell carcinoma, which constitutes 20-30% of all skin cancers, while malicious melanoma only 1.5-2%. Oncological surgery and radiotherapy are the most popular treatments of skin cancer, while chemotherapy is less applied. Results of the first two methods are comparable. Differences refer to frequency of occurrence, side effects, treatment and cosmetic effects having influence on the quality of patients' life. Third type of skin cancer - malicious melanoma - belongs to the group of the most aggressive, which hardly undergo treatment. The cytostatic drug being most active in monotherapy of melanoma is decarbazine. Other substances that demonstrate some/partial activity in treatment of malicious melanoma are: temozolomide, cis-platin, carboplatin, vinblastin, vincristine, paclitaxel, docetaxel.
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.